IPSC: רווח נקי למניה (EPS TTM) Century Tx

Earnings per share over the last 12 months demonstrate Century Therapeutics (IPSC) dependence on external capital due to a lack of market influence prior to the FDA verdict. The current level of -0.61 captures fresh values while the company relies on universal cell products for oncology centers. Growth prospects are supported by the patented iPSC platform and steady interest from venture capital funds in genetics.

For Century Therapeutics (IPSC), the 12-month earnings per share history serves as an indicator of how effectively the company is capitalizing on its stem cell platform. This metric calculates the rolling annual net income distributed across the total shares outstanding. Such an approach eliminates quarterly gaps, demonstrating the actual dynamics of equity earnings. For this biotech firm, this indicator is critical as it transitions toward commercial procurement of cancer therapies by insurers. An upward trend in the curve would confirm the successful monetization of universal products.